COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
39M of 33M shares
Institutional holders
279
45 new, 29 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $7.24M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,997,827 | 15.60% | 13G (passive) amendment | Mar 31, 2025 |
| David Rosen | 3,000,000 | 9.34% | 13G (passive) amendment | Mar 31, 2025 |
| Millennium Group Management LLC | 2,400,985 | 7.40% | 13G (passive) amendment | Sep 30, 2026 |
| Joe M. Thomson | 2,142,491 | 5.40% | 13G (passive) | Dec 31, 2024 |
| Janus Henderson Group PLC | 1,825,651 | 5.80% | 13G (passive) | Mar 31, 2026 |
| Millennium Management LLC | 1,820,330 | 5.60% | 13G (passive) | Aug 17, 2026 |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | 5.03% | 13G (passive) | Jun 30, 2026 |
| Principal Global Investors | 1,632,360 | 5.00% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 1,625,821 | 5.01% | 13G (passive) | Jun 30, 2026 |
| Renaissance Technologies Holdings Corporation | 1,599,189 | 5.06% | 13G (passive) | Sep 8, 2025 |
| Invesco Ltd. | 1,591,909 | 5.00% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COLL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,441,202 | 16.71% | $196.97M | +307,175 | 0.00% |
| Jupiter Topco LLC | 2,147,072 | 6.60% | $77.74M | New | 0.03% |
| Invesco Ltd. | 1,882,499 | 5.78% | $68.15M | +290,590 | 0.01% |
| Fuller & Thaler Asset Management, Inc. | 1,632,781 | 5.02% | $59.11M | +133,197 | 0.16% |
| Principal Financial Group Inc | 1,632,360 | 5.01% | $59.09M | +337,332 | 0.03% |
| State Street Corp | 1,528,881 | 4.70% | $55.35M | +104,337 | 0.00% |
| Massachusetts Financial Services Co /Ma/ | 1,405,567 | 4.32% | $50.88M | +39,635 | 0.02% |
| Vanguard Capital Management LLC | 1,381,261 | 4.24% | $50.00M | +47,269 | 0.00% |
| Renaissance Technologies LLC | 1,366,549 | 4.20% | $49.47M | −102,900 | 0.07% |
| Eventide Asset Management, LLC | 1,361,228 | 4.18% | $49.27M | −63,054 | 0.66% |
| Rubric Capital Management LP | 1,279,611 | 3.93% | $46.32M | – | 0.42% |
| Geode Capital Management, LLC | 890,886 | 2.74% | $32.26M | +71,446 | 0.00% |
| Dimensional Fund Advisors LP | 837,877 | 2.57% | $30.33M | +4,685 | 0.01% |
| Victory Capital Management Inc | 760,252 | 2.34% | $27.52M | +134,948 | 0.02% |
| Goldentree Asset Management LP | 744,889 | 2.29% | $26.92M | New | 1.56% |
| Vanguard Portfolio Management LLC | 740,081 | 2.27% | $26.79M | +59,700 | 0.00% |
| Millennium Management LLC | 736,925 | 2.26% | $26.68M | +376,099 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 621,920 | 1.91% | $22.51M | −81,608 | 0.01% |
| Assenagon Asset Management S.A. | 617,834 | 1.90% | $22.37M | +305,236 | 0.01% |
| Goldman Sachs Group Inc | 556,927 | 1.71% | $20.16M | −18,214 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 279 | 39M | 100.0% | 45 / 120 | 84 / 29 | 7M | 4M |
| Q1 2026 | 267 | 38M | 100.0% | 41 / 109 | 77 / 46 | 7M | 5M |
| Q4 2025 | 279 | 39M | 100.0% | 52 / 86 | 107 / 15 | 6M | 4M |
| Q3 2025 | 244 | 37M | 100.0% | 43 / 84 | 87 / 21 | 5M | 3M |
| Q2 2025 | 223 | 36M | 100.0% | 20 / 89 | 83 / 34 | 2M | 3M |
| Q1 2025 | 242 | 37M | 100.0% | 33 / 78 | 97 / 25 | 3M | 4M |
| Q4 2024 | 238 | 37M | 100.0% | 36 / 71 | 92 / 46 | 3M | 5M |
| Q3 2024 | 249 | 39M | 100.0% | 40 / 101 | 77 / 19 | 9M | 4M |
| Q2 2024 | 229 | 40M | 100.0% | 37 / 93 | 75 / 34 | 5M | 6M |
| Q1 2024 | 228 | 41M | 100.0% | 52 / 79 | 77 / 16 | 5M | 4M |
| Q4 2023 | 193 | 40M | 100.0% | 33 / 58 | 77 / 13 | 5M | 3M |
| Q3 2023 | 174 | 39M | 100.0% | 17 / 74 | 59 / 21 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of COLL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,954,487 | 6.00% | $70.75M | 0.06% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 1,561,408 | 4.80% | $56.52M | 0.45% | Jun 30, 2026 |
| Eventide Gilead Fund | 1,344,376 | 4.13% | $48.67M | 1.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 977,957 | 3.00% | $35.40M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 856,942 | 2.63% | $31.02M | 0.04% | Jun 30, 2026 |
| SmallCap Fund | 641,300 | 1.97% | $22.70M | 1.09% | Jul 31, 2026 |
| MFS New Discovery Fund | 585,155 | 1.80% | $19.67M | 0.92% | May 31, 2026 |
| Invesco Main Street Small Cap Fund | 411,484 | 1.26% | $14.90M | 0.56% | Jun 30, 2026 |
| MFS New Discovery Value Fund | 396,902 | 1.22% | $13.34M | 0.54% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 369,871 | 1.14% | $13.39M | 0.01% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 365,632 | 1.12% | $12.94M | 2.74% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 359,376 | 1.10% | $12.72M | 0.04% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 319,959 | 0.98% | $10.75M | 0.04% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 303,980 | 0.93% | $11.00M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 296,717 | 0.91% | $10.74M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vikram Karnani | President and CEO, Director | 176,629 | 0.54% | Feb 12, 2026 |
| David Dieter | EVP & General Counsel | 68,231 | 0.21% | Apr 3, 2026 |
| Scott Dreyer | EVP & Chief Commercial Officer | 75,329 | 0.23% | Mar 5, 2026 |
| Thomas B. Smith | EVP and Chief Medical Officer | 85,312 | 0.26% | Feb 12, 2026 |
| Colleen Tupper | EVP & Chief Financial Officer | 147,282 | 0.45% | Feb 12, 2026 |
| Shirley R. Kuhlmann | EVP and General Counsel | 108,137 | 0.33% | Mar 6, 2025 |
| Gino Santini | Director | 112,483 | 0.35% | Jun 10, 2026 |
| John Gordon Freund | Director | 115,706 | 0.36% | May 20, 2026 |
| Donovan Michael Glancy | Director | 17,482 | 0.05% | May 18, 2026 |
| Nancy Lurker | Director | 26,758 | 0.08% | May 18, 2026 |
| Garen G. Bohlin | Director | 71,000 | 0.22% | May 18, 2026 |
| Carlos V. Paya | Director | 28,323 | 0.09% | May 18, 2026 |
| Rita J. Balice-Gordon | Director | 61,370 | 0.19% | May 18, 2026 |
| John A. Fallon | Director | 99,487 | 0.31% | Nov 14, 2025 |
| Michael Thomas Heffernan | Director | 213,371 | 0.66% | Feb 12, 2025 |
| Capital Management LP Rubric | 10% owner | 3,132,743 | 9.62% | Aug 15, 2025 |
| David Efraim Rosen | 10% owner | 3,157,743 | 9.70% | Aug 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gino Santini Director | Jun 8, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 112,483 |
| John Gordon Freund Director | May 18, 2026 | Sale | −20 | $34.05 | $681 | 83,952 |
| John Gordon Freund Director | May 15, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 88,099 |
| John Gordon Freund Director | May 15, 2026 | Sale | −4,127 | $34.54 | $142.55K | 83,972 |
| Gino Santini Director | May 14, 2026 | Award | +8,741 | – | – | 103,783 |
| Rita J. Balice-Gordon Director | May 14, 2026 | Award | +8,741 | – | – | 61,370 |
| John Gordon Freund Director | May 14, 2026 | Award | +8,741 | – | – | 79,399 |
| Carlos V. Paya Director | May 14, 2026 | Award | +8,741 | – | – | 28,323 |
| Nancy Lurker Director | May 14, 2026 | Award | +8,741 | – | – | 26,758 |
| Garen G. Bohlin Director | May 14, 2026 | Award | +8,741 | – | – | 71,000 |
| Donovan Michael Glancy Director | May 14, 2026 | Award | +17,482 | – | – | 17,482 |
| Nancy Lurker Director | May 13, 2026 | Sale | −4,500 | $35.97 | $161.87K | 18,017 |
| Garen G. Bohlin Director | May 11, 2026 | Option exercise | +8,700 | $16.49 | $143.46K | 70,959 |
| Garen G. Bohlin Director | May 11, 2026 | Sale | −8,700 | $37.18 | $323.47K | 62,259 |
| David Dieter EVP & General Counsel | Mar 18, 2026 | Sale(10b5-1 plan) | −13,976 | $34.92 | $488.04K | 77,071 |
| David Dieter EVP & General Counsel | Mar 17, 2026 | Tax withholding | −8,840 | $35.72 | $315.76K | 68,231 |
| David Dieter EVP & General Counsel | Mar 9, 2026 | Sale(10b5-1 plan) | −6,224 | $36.65 | $228.11K | 91,047 |
| Scott Dreyer EVP & Chief Commercial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −46,417 | $40.36 | $1.87M | 75,329 |
| Scott Dreyer EVP & Chief Commercial Officer | Mar 3, 2026 | Sale(10b5-1 plan) | −3,559 | $40.99 | $145.88K | 71,770 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Tax withholding | −2,781 | $46.75 | $130.01K | 97,271 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Award | +9,005 | – | – | 100,052 |
| David Dieter EVP & General Counsel | Feb 10, 2026 | Award | +22,194 | – | – | 91,047 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Award | +14,268 | – | – | 85,312 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Award | +22,774 | – | – | 108,086 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Tax withholding | −11,538 | $46.75 | $539.40K | 90,651 |
| Thomas B. Smith EVP and Chief Medical Officer | Feb 10, 2026 | Tax withholding | −5,897 | $46.75 | $275.68K | 102,189 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Award | +19,023 | – | – | 122,636 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Award | +30,702 | – | – | 153,338 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −9,977 | $46.75 | $466.42K | 143,361 |
| Scott Dreyer EVP & Chief Commercial Officer | Feb 10, 2026 | Tax withholding | −21,615 | $46.75 | $1.01M | 121,746 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −26,679 | $46.75 | $1.25M | 147,282 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Tax withholding | −11,861 | $46.75 | $554.50K | 173,961 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Award | +26,421 | – | – | 153,088 |
| Colleen Tupper EVP & Chief Financial Officer | Feb 10, 2026 | Award | +32,734 | – | – | 185,822 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Award | +79,264 | – | – | 176,629 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Award | +32,531 | – | – | 209,160 |
| Vikram Karnani President and CEO, Director | Feb 10, 2026 | Tax withholding | −11,296 | $46.75 | $528.09K | 197,864 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Option exercise | +17,600 | $15.90 | $279.84K | 121,213 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −6,475 | $48.66 | $315.07K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −11,125 | $47.89 | $532.78K | 110,088 |
| Rita J. Balice-Gordon Director | Dec 5, 2025 | Sale | −3,650 | $47.03 | $171.66K | 52,629 |
| Vikram Karnani President and CEO, Director | Nov 12, 2025 | Tax withholding | −8,983 | $47.35 | $425.35K | 96,989 |
| John A. Fallon Director | Nov 12, 2025 | Option exercise | +19,853 | $9.33 | $185.23K | 99,487 |
| John A. Fallon Director | Nov 12, 2025 | Sale | −34,853 | $47.21 | $1.65M | 64,634 |
| John A. Fallon Director | Nov 12, 2025 | Option exercise | +15,000 | $16.49 | $247.35K | 79,634 |
| Colleen Tupper EVP & Chief Financial Officer | Nov 6, 2025 | Sale(10b5-1 plan) | −4,858 | $41.28 | $200.54K | 126,667 |
| Colleen Tupper EVP & Chief Financial Officer | Nov 6, 2025 | Sale(10b5-1 plan) | −25,142 | $40.38 | $1.02M | 131,525 |
| Thomas B. Smith EVP and Chief Medical Officer | Aug 29, 2025 | Sale | −17,478 | $38.42 | $671.50K | 70,264 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 18, 2025 | Sale(10b5-1 plan) | −16,389 | $38.21 | $626.22K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 18, 2025 | Option exercise | +16,389 | $21.34 | $349.74K | 120,002 |
| Gino Santini Director | Aug 15, 2025 | Sale | −5,405 | $37.19 | $201.01K | 95,042 |
| Gino Santini Director | Aug 15, 2025 | Option exercise | +15,000 | $13.45 | $201.75K | 100,447 |
| Capital Management LP Rubric 10% owner | Aug 13, 2025 | Sale | −25,000 | $37.85 | $946.25K | 3,132,743 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 13, 2025 | Sale(10b5-1 plan) | −4,861 | $38.03 | $184.86K | 103,613 |
| Scott Dreyer EVP & Chief Commercial Officer | Aug 13, 2025 | Option exercise | +4,861 | $21.34 | $103.73K | 108,474 |
| John Gordon Freund Director | Aug 8, 2025 | Sale | −11,659 | $34.36 | $400.60K | 23,129 |
| John Gordon Freund Director | Jun 9, 2025 | Sale | −6,601 | $30.62 | $202.12K | 70,658 |
| John Gordon Freund Director | Jun 9, 2025 | Option exercise | +15,000 | $13.45 | $201.75K | 77,259 |
| Nancy Lurker Director | May 15, 2025 | Award | +9,791 | – | – | 22,517 |
| Gino Santini Director | May 15, 2025 | Award | +9,791 | – | – | 85,447 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Scott Dreyer Former Officer | Sep 30, 2026 | 27,419 | $603.32K | Sep 30, 2026 | Restricted Stock Vesting |
| John A. Fallon Former Director | Jul 17, 2026 | 13,920 | $497.43K | Jul 17, 2026 | Stock Option Exercise |
| John A. Fallon Former Director | Jul 15, 2026 | 8,095 | $294.01K | Jul 15, 2026 | Stock Option Exercise |
| John Gordon Freund Director | May 18, 2026 | 30 | $1.02K | May 18, 2026 | Restricted Stock Vesting |
| John Gordon Freund Director | May 15, 2026 | 4,127 | $142.55K | May 15, 2026 | Option Granted - 06/09/2016 |
| Nancy Lurker Director | May 13, 2026 | 4,500 | $161.86K | May 13, 2026 | Restricted Stock Vesting |
| Garen G. Bohlin Director | May 11, 2026 | 8,700 | $323.49K | May 11, 2026 | Option Granted - 06/09/2016 |
| David Dieter Officer | Mar 18, 2026 | 13,976 | $488.10K | Mar 18, 2026 | Restricted Stock Vesting |
| David Dieter Officer | Mar 9, 2026 | 6,224 | $228.11K | Mar 9, 2026 | Restricted Stock Vesting |
| Scott Dreyer Officer | Mar 3, 2026 | 49,976 | $2.02M | Mar 3, 2026 | Restricted Stock Vesting |
| Balice-Gordon Rita DIRECTOR | Dec 17, 2025 | 3,650 | $171.67K | Dec 5, 2025 | VESTING OF RESTRICTED STOCK UNITS |
| Scott Dreyer Officer | Dec 8, 2025 | 17,600 | $847.86K | Dec 8, 2025 | Options Granted - 01/25/2019 |
| John A. Fallon Director | Nov 12, 2025 | 34,853 | $1.65M | Nov 12, 2025 | Option Granted - 06/09/2016 |
| Colleen Tupper Officer | Nov 6, 2025 | 30,000 | $1.22M | Nov 6, 2025 | Restricted Stock Vesting |
| Thomas B. Smith Officer | Aug 29, 2025 | 17,478 | $671.58K | Aug 29, 2025 | Vested RSUs |